Collaboration to develop more accurate prognosis for bladder and prostate cancer patients.
U.S. Genomics and Lahey Clinic will study the role microRNAs play in the development of urologic cancers, according to a a discovery agreement between them. The company’s report that the objective of is to develop more accurate prognoses for bladder and prostate cancer patients.
“This collaboration is intended to expedite the development of next-generation molecular diagnostic tests to determine the prognosis of several major urologic cancers,” comments John Libertino, M.D., chairman of the department of urology, Lahey Clinic.
The collaboration combines U.S. Genomics’ patented Trilogy® 2020 platform and Direct™ miRNA assay with Lahey Clinic’s expertise in the analysis of tumor progression and experience in disease management.